Table 1 Characteristics of the studies.
Study | Year | Country | Patient type | FMT mode | Control mode | Delivery route | Donor type | Evaluation time | Total dose of FMT |
|---|---|---|---|---|---|---|---|---|---|
Kedia et al.8 | 2022 | India | Mild to moderate UC | FMT-AID | SMT | Colonoscopy | Multiple donors | Week 8 | 350.0 g |
Sarbagili et al.9 | 2022 | Israel | Active UC | FMT + UCED | UCED | Colonoscopy and enema | Single donor | Week 8 | 133.3 g |
Haifer et al.10 | 2022 | Australia | Active UC | FMT | Placebo | Oral capsules | Single donor | Week 8 | 102.9 g |
Crothers et al.11 | 2021 | United States | Mild to moderate UC | FMT | Placebo | Colonoscopy and oral capsules | Multiple donors | Week 12 | 90.0 g |
Březina et al.12 | 2021 | Czech Republic | Active left-sided UC | FMT | 5-ASA | Enema | Single donor | Week 12 | 500.0 g |
Pai et al.13 | 2021 | Canada | Pediatric active UC | FMT | Placebo | Enema | Multiple donors | Week 30 | 600.0 g |
Fang et al.14 | 2021 | China | Recurrent active UC | FMT | 5-ASA | Colonoscopy | Single donor | Week 8 | 50.0 g |
Schierová et al.15 | 2020 | Czech Republic | Active left-sided UC | FMT | 5-ASA | Enema | Single donor | Week 12 | 500.0 g |
Sood et al.16 | 2019 | India | Active UC | FMT + SOC | Placebo + SOC | Colonoscopy | Single donor | Week 48 | 700.0 g |
Costello et al.17 | 2019 | Australia | Mild to moderate active UC | FMT | Autologous FMT | Colonoscopy and enema | Multiple donors | Week 8 | 100.0 g |
Paramsothy et al.18 | 2017 | Australia | Active UC | FMT | Placebo | Colonoscopy and enema | Multiple donors | Week 8 | 1537.5 g |
Rossen et al.19 | 2015 | The Netherlands | Mild to moderate active UC | FMT | Autologous FMT | Nasoduodenal tube | Single donor | Week 12 | 240.0 g |
Moayyedi et al.20 | 2015 | Canada | Active UC | FMT | Placebo | Enema | Single donor | Week 7 | 300.0 g |
